Co-Diagnostics, Inc. (NASDAQ:CODX) Stock Short Interest Report for October

Co-Diagnostics, Inc. (NASDAQ:CODX – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 30th, there was short interest totaling 981,329 shares, an increase of 49.5% from the October 15th total of 656,373 shares. Approximately 10.5% of the company’s stock are sold short. Based on an average trading volume of 438,760 shares, the days-to-cover ratio is currently 2.2 days.

Institutional Investors Weigh In On Co-Diagnostics

An institutional investor recently bought a new stake in Co-Diagnostics stock. Susquehanna International Group LLP bought a new position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 31,239 shares of the company’s stock, valued at approximately $97,000. Susquehanna International Group LLP owned 0.85% of Co-Diagnostics at the end of the most recent quarter. 14.99% of the stock is owned by institutional investors.

Co-Diagnostics Stock Up 0.9%

Shares of Co-Diagnostics stock opened at $0.20 on Thursday. Co-Diagnostics has a 52 week low of $0.17 and a 52 week high of $13.54. The company has a market capitalization of $2.08 million, a price-to-earnings ratio of -0.03 and a beta of 3.15. The stock’s 50-day simple moving average is $0.74 and its 200-day simple moving average is $2.04.

Co-Diagnostics (NASDAQ:CODX – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.24. The company had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.17 million. Co-Diagnostics had a negative net margin of 5,530.54% and a negative return on equity of 322.92%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CODX shares. Weiss Ratings lowered shares of Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 11th. Maxim Group upgraded Co-Diagnostics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 18th. Finally, Wall Street Zen upgraded shares of Co-Diagnostics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Co-Diagnostics currently has an average rating of “Hold” and an average target price of $45.00.

Check Out Our Latest Analysis on CODX

About Co-Diagnostics

(Get Free Report)

Co-Diagnostics, Inc. is a molecular diagnostics company that develops technologies and tests for detecting infectious diseases. Based in Salt Lake City, Utah, the company’s work centers on its proprietary CoPrimer technology, used to design assays for polymerase chain reaction (PCR) testing. Its products include PCR-based diagnostic tests and related instruments, including the Co-Dx PCR platform. The company has developed tests for a range of infectious diseases, with product availability and regulatory status varying by market.

Featured Articles

Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.